Rhumbline Advisers Buys 24,802 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)

Rhumbline Advisers lifted its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 13.3% in the 2nd quarter, Holdings Channel reports. The fund owned 211,677 shares of the company’s stock after acquiring an additional 24,802 shares during the quarter. Rhumbline Advisers’ holdings in ImmunityBio were worth $1,338,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. CIBC Asset Management Inc bought a new stake in shares of ImmunityBio during the second quarter worth $118,000. Bank of New York Mellon Corp increased its position in shares of ImmunityBio by 37.9% during the second quarter. Bank of New York Mellon Corp now owns 621,536 shares of the company’s stock worth $3,928,000 after acquiring an additional 170,742 shares in the last quarter. Simplicity Wealth LLC increased its position in shares of ImmunityBio by 46.0% during the second quarter. Simplicity Wealth LLC now owns 15,806 shares of the company’s stock worth $100,000 after acquiring an additional 4,983 shares in the last quarter. Collective Family Office LLC bought a new stake in shares of ImmunityBio during the second quarter worth $445,000. Finally, DekaBank Deutsche Girozentrale increased its position in shares of ImmunityBio by 4.5% during the first quarter. DekaBank Deutsche Girozentrale now owns 205,092 shares of the company’s stock worth $1,119,000 after acquiring an additional 8,892 shares in the last quarter. Institutional investors own 8.58% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Piper Sandler lowered their price objective on shares of ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a research report on Monday, August 19th.

ImmunityBio Trading Up 1.1 %

Shares of IBRX opened at $3.52 on Friday. ImmunityBio, Inc. has a 12 month low of $1.25 and a 12 month high of $10.53. The firm has a fifty day simple moving average of $4.40 and a 200 day simple moving average of $5.65. The stock has a market capitalization of $2.43 billion, a price-to-earnings ratio of -3.23 and a beta of 1.02.

ImmunityBio (NASDAQ:IBRX) last announced its earnings results on Monday, August 12th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.53 million. As a group, research analysts predict that ImmunityBio, Inc. will post -0.86 earnings per share for the current fiscal year.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.